Gene therapy of liver tumors with human liver-specific nanoparticles

Y. Iwasaki, M. Ueda, T. Yamada, A. Kondo, M. Seno, K. Tanizawa, S. Kuroda, Michiie Sakamoto, M. Kitajima

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The development of safe and efficient liver-specific gene delivery approaches offers new perspectives for the treatment of liver disease, in particular, liver cancer. We evaluated the therapeutic potential of hepatotropic nanoparticles for gene therapy of liver tumor. These nanoparticles do not contain a viral genome and display the hepatitis B virus L antigen, which is essential to confer hepatic specificity. It has not been shown whether a therapeutic effect could be obtained using L nanoparticles in a human liver tumor xenograft model. Rats bearing human hepatic (NuE) and non-hepatic tumors were injected with L nanoparticles containing a green fluorescent protein (GFP) expression plasmid. GFP expression was observed only in NuE-derived tumors but not in the non-hepatic tumor. The potential for treatment of liver tumors was analyzed using L nanoparticles containing the herpes simplex virus thymidine kinase gene, in conjunction with ganciclovir pro-drug administration. The growth of NuE-derived tumors in L particle-injected rats was significantly suppressed, but not of the non-hepatic tumor control. In summary, this is the first demonstration that nanoparticles could be used for delivery of therapeutic genes with anti-tumor activity into human liver tumors. This intravenous delivery system may be one of the major advantages as compared to many other viral vector systems.

Original languageEnglish
Pages (from-to)74-81
Number of pages8
JournalCancer Gene Therapy
Volume14
Issue number1
DOIs
Publication statusPublished - 2007 Jan 22

Fingerprint

Genetic Therapy
Nanoparticles
Liver
Neoplasms
Green Fluorescent Proteins
Genes
Ganciclovir
Thymidine Kinase
Viral Genome
Prodrugs
Therapeutic Uses
Simplexvirus
Therapeutics
Liver Neoplasms
Heterografts
Hepatitis B virus
Human Activities
Liver Diseases
Plasmids
Growth

Keywords

  • Gene therapy
  • HBsAg L nanoparticle
  • HSV-tk/GCV system
  • Liver tumor

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Iwasaki, Y., Ueda, M., Yamada, T., Kondo, A., Seno, M., Tanizawa, K., ... Kitajima, M. (2007). Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Therapy, 14(1), 74-81. https://doi.org/10.1038/sj.cgt.7700990

Gene therapy of liver tumors with human liver-specific nanoparticles. / Iwasaki, Y.; Ueda, M.; Yamada, T.; Kondo, A.; Seno, M.; Tanizawa, K.; Kuroda, S.; Sakamoto, Michiie; Kitajima, M.

In: Cancer Gene Therapy, Vol. 14, No. 1, 22.01.2007, p. 74-81.

Research output: Contribution to journalArticle

Iwasaki, Y, Ueda, M, Yamada, T, Kondo, A, Seno, M, Tanizawa, K, Kuroda, S, Sakamoto, M & Kitajima, M 2007, 'Gene therapy of liver tumors with human liver-specific nanoparticles', Cancer Gene Therapy, vol. 14, no. 1, pp. 74-81. https://doi.org/10.1038/sj.cgt.7700990
Iwasaki Y, Ueda M, Yamada T, Kondo A, Seno M, Tanizawa K et al. Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Therapy. 2007 Jan 22;14(1):74-81. https://doi.org/10.1038/sj.cgt.7700990
Iwasaki, Y. ; Ueda, M. ; Yamada, T. ; Kondo, A. ; Seno, M. ; Tanizawa, K. ; Kuroda, S. ; Sakamoto, Michiie ; Kitajima, M. / Gene therapy of liver tumors with human liver-specific nanoparticles. In: Cancer Gene Therapy. 2007 ; Vol. 14, No. 1. pp. 74-81.
@article{90057f7b13eb44c1a75fcfb8cfbaaa6e,
title = "Gene therapy of liver tumors with human liver-specific nanoparticles",
abstract = "The development of safe and efficient liver-specific gene delivery approaches offers new perspectives for the treatment of liver disease, in particular, liver cancer. We evaluated the therapeutic potential of hepatotropic nanoparticles for gene therapy of liver tumor. These nanoparticles do not contain a viral genome and display the hepatitis B virus L antigen, which is essential to confer hepatic specificity. It has not been shown whether a therapeutic effect could be obtained using L nanoparticles in a human liver tumor xenograft model. Rats bearing human hepatic (NuE) and non-hepatic tumors were injected with L nanoparticles containing a green fluorescent protein (GFP) expression plasmid. GFP expression was observed only in NuE-derived tumors but not in the non-hepatic tumor. The potential for treatment of liver tumors was analyzed using L nanoparticles containing the herpes simplex virus thymidine kinase gene, in conjunction with ganciclovir pro-drug administration. The growth of NuE-derived tumors in L particle-injected rats was significantly suppressed, but not of the non-hepatic tumor control. In summary, this is the first demonstration that nanoparticles could be used for delivery of therapeutic genes with anti-tumor activity into human liver tumors. This intravenous delivery system may be one of the major advantages as compared to many other viral vector systems.",
keywords = "Gene therapy, HBsAg L nanoparticle, HSV-tk/GCV system, Liver tumor",
author = "Y. Iwasaki and M. Ueda and T. Yamada and A. Kondo and M. Seno and K. Tanizawa and S. Kuroda and Michiie Sakamoto and M. Kitajima",
year = "2007",
month = "1",
day = "22",
doi = "10.1038/sj.cgt.7700990",
language = "English",
volume = "14",
pages = "74--81",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Gene therapy of liver tumors with human liver-specific nanoparticles

AU - Iwasaki, Y.

AU - Ueda, M.

AU - Yamada, T.

AU - Kondo, A.

AU - Seno, M.

AU - Tanizawa, K.

AU - Kuroda, S.

AU - Sakamoto, Michiie

AU - Kitajima, M.

PY - 2007/1/22

Y1 - 2007/1/22

N2 - The development of safe and efficient liver-specific gene delivery approaches offers new perspectives for the treatment of liver disease, in particular, liver cancer. We evaluated the therapeutic potential of hepatotropic nanoparticles for gene therapy of liver tumor. These nanoparticles do not contain a viral genome and display the hepatitis B virus L antigen, which is essential to confer hepatic specificity. It has not been shown whether a therapeutic effect could be obtained using L nanoparticles in a human liver tumor xenograft model. Rats bearing human hepatic (NuE) and non-hepatic tumors were injected with L nanoparticles containing a green fluorescent protein (GFP) expression plasmid. GFP expression was observed only in NuE-derived tumors but not in the non-hepatic tumor. The potential for treatment of liver tumors was analyzed using L nanoparticles containing the herpes simplex virus thymidine kinase gene, in conjunction with ganciclovir pro-drug administration. The growth of NuE-derived tumors in L particle-injected rats was significantly suppressed, but not of the non-hepatic tumor control. In summary, this is the first demonstration that nanoparticles could be used for delivery of therapeutic genes with anti-tumor activity into human liver tumors. This intravenous delivery system may be one of the major advantages as compared to many other viral vector systems.

AB - The development of safe and efficient liver-specific gene delivery approaches offers new perspectives for the treatment of liver disease, in particular, liver cancer. We evaluated the therapeutic potential of hepatotropic nanoparticles for gene therapy of liver tumor. These nanoparticles do not contain a viral genome and display the hepatitis B virus L antigen, which is essential to confer hepatic specificity. It has not been shown whether a therapeutic effect could be obtained using L nanoparticles in a human liver tumor xenograft model. Rats bearing human hepatic (NuE) and non-hepatic tumors were injected with L nanoparticles containing a green fluorescent protein (GFP) expression plasmid. GFP expression was observed only in NuE-derived tumors but not in the non-hepatic tumor. The potential for treatment of liver tumors was analyzed using L nanoparticles containing the herpes simplex virus thymidine kinase gene, in conjunction with ganciclovir pro-drug administration. The growth of NuE-derived tumors in L particle-injected rats was significantly suppressed, but not of the non-hepatic tumor control. In summary, this is the first demonstration that nanoparticles could be used for delivery of therapeutic genes with anti-tumor activity into human liver tumors. This intravenous delivery system may be one of the major advantages as compared to many other viral vector systems.

KW - Gene therapy

KW - HBsAg L nanoparticle

KW - HSV-tk/GCV system

KW - Liver tumor

UR - http://www.scopus.com/inward/record.url?scp=33845626643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845626643&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700990

DO - 10.1038/sj.cgt.7700990

M3 - Article

VL - 14

SP - 74

EP - 81

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 1

ER -